24 recruiting, 11 not yet recruiting, 5 completed, 4 terminated. 28 Phase 1, 8 Phase 2, 4 Not applicable, 3 Early Phase 1, 2 Phase 4.
Follow Solid Tumor Malignancies: new trials by email Literature Review of Solid Tumor Malignancies trials Research Report on Solid Tumor Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors SND002 Cell Injection - Colorectal Neoplasms, Stomach Neoplasms | Phase 1 | Not yet recruiting | Guizhou Sinorda Pharmaceutical Co., Ltd. | 78 | 2026-12-01 | 2026-10-29 |
| The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy 18F-G1 - Solid Tumor Malignancies, Hematologic Cancer | Recruiting | Peking University First Hospital | 120 | 2026-09-08 | 2026-09-28 | |
| GKL-006Allo Injection in Patients With Advanced Solid Tumors GKL-006Allo Injection - Solid Tumor Malignancies | Phase 1 | Not yet recruiting | Beijing Gene Key Life Technology Co., Ltd | 27 | 2026-08-30 | 2026-07-15 |
| A Clinical Study of GO321 in Patients With Advanced Solid Tumors GO321 - Solid Tumor Malignancies | Phase 1 | Not yet recruiting | GeneSail Biotech (Shanghai) Co., Ltd. | 21 | 2026-08-15 | 2026-08-05 |
| Clinical Evaluation of [68Ga]Ga-FFD PET Imaging in Healthy Volunteers and Patients With Solid Tumors [68Ga]Ga-FFD - Solid Tumor Malignancies | Early Phase 1 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-07-30 | 2026-07-16 |
| A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors FG-B901, FG-M108 - Claudin 18.2, Solid Tumor Malignancies | Phase 1 / Phase 2 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 120 | 2026-07-30 | 2026-07-15 |
| Imaging Study of [89Zr]DFO-YS5 for Cancer Detection [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 40 | 2026-06-15 | 2026-10-01 |
| Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) Pedmark® STS - Solid Tumor Malignancies, Testicular Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 25 | 2026-05-18 | 2026-06-18 |
| Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinical Study) Bloodsampling, Pharyngeal swab sampling, Cuteanous swab sampling - Solid Tumor Malignancies, Solid Cancers | Not applicable | Recruiting | Assistance Publique Hopitaux De Marseille | 160 | 2026-03-23 | 2026-10-28 |
| Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. Valemetostat Tosylate - Solid Tumor Malignancies, Clear Cell Endometrial Carcinoma | Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 900 | 2026-03-05 | 2026-04-21 |
| Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive - NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer | Phase 4 | Recruiting | Rigel Pharmaceuticals | 12 | 2026-03-04 | 2026-08-10 |
| Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression Solid Tumor Malignancies | Not yet recruiting | The First Affiliated Hospital of Xinxiang Medical College | 100 | 2026-03-01 | 2026-03-17 | |
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Recruiting | Rigel Pharmaceuticals | 16 | 2026-02-23 | 2026-08-11 |
| Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors TYK-01054 - Solid Tumor Malignancies, Malignant Mesothelioma (MM) | Phase 1 / Phase 2 | Not yet recruiting | TYK Medicines, Inc | 219 | 2026-01-01 | 2025-12-22 |
| Malic Acid Supplementation Combined With Immunotherapy in Patients With Solid Tumors Malic Acid - Solid Tumor Malignancies | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital of Xinxiang Medical College | 30 | 2025-12-31 | 2026-01-08 |
| Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study One time CSF and blood sample - Solid Tumor Malignancies, Brain Metastasases | Not applicable | Recruiting | Sunnybrook Health Sciences Centre | 60 | 2025-12-12 | 2026-07-31 |
| A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia SXRN Injection - Cachexia-Anorexia Syndrome, Solid Tumor Malignancies | Phase 1 | Recruiting | Jiangsu Nutai Biologics Co., Ltd | 54 | 2025-11-17 | 2025-12-08 |
| xDRIVE for Florida-based Cancer Patients xDRIVE Tumor Profiling - Cancer, Neoplams | Not applicable | Recruiting | First Ascent Biomedical Inc. | 210 | 2025-11-01 | 2026-05-19 |
| 68Ga-GP-01 Injection in Solid Tumors Participants 68Ga-GP-01 Injection - Solid Tumor Malignancies | Phase 1 | Not yet recruiting | GrandPharma (China) Co., Ltd. | 20 | 2025-10-31 | 2025-07-03 |
Showing 20 of 45. Sign in to see all of them.
Neoplasms (9) · Neoplasm Metastasis (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Lung Neoplasms (4) · Breast Neoplasms (3) · Esophageal Neoplasms (3) · Stomach Neoplasms (3) · Urinary Bladder Neoplasms (3) · Hematologic Neoplasms (2) · Hypoxia (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Necrosis (2) · Recurrence (2)
Neoplasms by Site (15) · Neoplasms (13) · Digestive System Diseases (8) · Gastrointestinal Diseases (8) · Neoplasms by Histologic Type (8) · Pathological Conditions, Signs and Symptoms (8) · Respiratory Tract Diseases (8) · Digestive System Neoplasms (7) · Gastrointestinal Neoplasms (7) · Lung Diseases (7) · Pathologic Processes (7) · Respiratory Tract Neoplasms (7) · Thoracic Neoplasms (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7)
pembrolizumab (3) · Bacterial Load (2) · Blood Specimen Collection (2) · Cytochrome P-450 CYP2C8 (2) · Cytochrome P-450 CYP3A (2) · Cetuximab (1) · Cytochrome P-450 CYP1A2 (1) · Cytochrome P-450 CYP2B6 (1) · Cytochrome P-450 CYP2C19 (1) · Cytochrome P-450 CYP2C9 (1) · Extracorporeal Membrane Oxygenation (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · STA 9090 (1) · Valproic Acid (1)
Kumquat Biosciences Inc. (3) · BioMed Valley Discoveries, Inc (2) · GeneSail Biotech (Shanghai) Co., Ltd. (2) · Rigel Pharmaceuticals (2) · The First Affiliated Hospital of Xinxiang Medical College (2) · A2A Pharmaceuticals Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Beijing Gene Key Life Technology Co., Ltd (1) · Beijing StoneWise Technology Co., Ltd (1) · Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center (1) · Children's Mercy Hospital Kansas City (1) · First Ascent Biomedical Inc. (1) · FutureGen Biopharmaceutical (Beijing) Co., Ltd (1) · Geron Corporation (1) · GrandPharma (China) Co., Ltd. (1)
United States (21) · China (15) · France (2) · Australia (1) · Canada (1) · Spain (1) · Turkey (Türkiye) (1)
Alejandro Recio-Boiles, MD (1) · Anish Thomas, MBBS, MD (1) · Anup Kasi, MD (1) · Binghe Xu (1) · Carrie Lee (1) · David Nanus, M.D. (1) · Gheath Al-Atrash (1) · Jianhua Chang (1) · Lisa Davis, PharmD (1) · Ning Li, MD (1) · Robert Flavell, MD (1)
PMID 31811682, PMID 33046513, PMID 42711927
2023 (1), R21CA240881 (1), R42CA217482 (1)